2234-45-9

Basic information

• Product Name: 2-(BENZYLOXY)-6-BROMONAPHTHALENE
• Synonyms: BENZYL 6-BROMO-2-NAPHTHYL ETHER;2-(BENZYLOXY)-6-BROMONAPHTHALENE
• CAS NO: 2234-45-9
• Molecular Formula: C₁₇H₁₃BrO
• Molecular Weight: 313.19
• Mol File: 2234-45-9.mol
• Article Data: 19

Chemical Properties

• Melting Point: 112-113 °C
• Boiling Point: 434.6±20.0 °C(Predicted)
• Appearance: /
• Density: 1.395±0.06 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 2-(BENZYLOXY)-6-BROMONAPHTHALENE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BENZYLOXY)-6-BROMONAPHTHALENE(2234-45-9)
• EPA Substance Registry System: 2-(BENZYLOXY)-6-BROMONAPHTHALENE(2234-45-9)

Safety Data

• Hazardous Substances Data: 2234-45-9(Hazardous Substances Data)

Usage

General Description

2-(Benzyloxy)-6-bromonaphthalene is a chemical compound with the molecular formula C18H13BrO. It is a member of the naphthalene family and is characterized by a bromine atom and a benzyloxy group attached to the naphthalene ring. 2-(BENZYLOXY)-6-BROMONAPHTHALENE is used in organic synthesis and research as a building block for the synthesis of various organic compounds. It is also used as a precursor in the production of pharmaceuticals, agrochemicals, and other fine chemicals. 2-(Benzyloxy)-6-bromonaphthalene has potential applications in the pharmaceutical industry and is a valuable intermediate for the production of diverse organic compounds.

Upstream product

• 15231-91-1 6-bromo-naphthalen-2-ol 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 55476-88-5 N-benzyl-N-methylmorpholinium chloride 
• 42790-42-1 4-aza-1-benzylazoniabicyclo<2.2.2>octane chloride 

Downstream Products

• 1027728-64-8 [4-(6-Benzyloxy-naphthalen-2-yloxy)-phenyl]-acetic acid methyl ester 
• 114804-77-2 1,2,3,4-tetrahydro-6-benzyloxy-2-naphthoic acid 
• 1026524-29-7 [4-(6-Benzyloxy-naphthalen-2-yloxy)-phenyl]-acetyl chloride 
• 186890-96-0 4-(6-benzyloxy-2-naphthoxy)phenylacetic acid 
• 174567-99-8 2-((4-(6-benzyloxy-2-naphthyloxy)phenyl)acetylamino)benzoic acid methyl ester 
• 136241-83-3 2-benzyloxy-6-(1-hydroxyethyl)naphthalene 
• 1083313-89-6 N-(4-methylbenzyl)-6-(benzyloxy)naphthalen-2-amine 
• 301298-99-7 2-Benzyloxy-6-isocyanato-naphthalene 
• 122179-30-0 2-benzyloxynaphthalene-6-carboxylic acid chloride 
• 244103-66-0 (E)-3-[2-(6-Benzyloxy-naphthalen-2-ylmethyl)-phenyl]-acrylic acid 
• 152915-83-8 (6-(benzyloxy)naphthalen-2-yl)boronic acid 
• 2041-17-0 2-benzyloxy-6-hydroxynaphthalene 
• 66217-29-6 6-(benzyloxy)-2-cyanonaphthalene 

Relevant articles and documents

A new high twisting power material for use as a single asymmetric dopant in cholesteric displays with a temperature independence of the helical twisting power

The synthesis of a novel chiral non-racemic TADDOL derivative is presented and discussed. When the material is placed in a suitable nematic host it forms a chiral nematic phase which has an independence of the helical twisting power (HTP) with temperature

(PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER

The present invention relates to (piperidin-3-yl)(naphthalen-2-yl) methanone derivatives and related compounds as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The invention provides compounds of Formula (I) : wherein R1 is hydrogen, OH, halo, -CN, -NO2, -N=0, -NHOQ2, -OQ2, -SOQ2, -SO2Q2, -SON(Q2)2, - SO2N(Q2)2, -N(Q2)2, -C(O)OQ2, -C(O)Q2, -C(O)N(Q2)2, -C(=NQ2)NQ2, -NQ2C(=NQ2)NQ2, - C(O)N(Q2)(OQ2), -N(Q2)C(O)-Q2, -N(Q2)C(O)N(Q2)2, -N(Q2)C(O)O-Q2, -N(Q2)SO2Q2, -N(Q2)SOQ2, aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, or heteroaryl ring, each aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, and heteroaryl ring optionally including 1-3 substituents independently selected Q3; R2 and R3 are each independently hydrogen, OH, oxo, aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, optionally substituted with 1-3 of Q1 or Q2; X is a branched or straight C1-12 aliphatic chain wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, -CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, - O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, -SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-; G and G1 are each independently a branched or straight C1-2 aliphatic chain, or heterocycloalkyl, wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, - CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, -O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, - SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-, and pharmaceutically acceptable salts, solvates or prodaigs thereof, as well as methods of treating estrogen receptor mediated diseases and disorders using the compounds of Formula (I).

N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

This invention relates to novel N-piperidin-4-ylmethyl amide derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy, and to pharmaceutical compositions comprising the compounds of the invention.